Table 4 of
Nieto-Miguel, Mol Vis 2011; 17:2102-2117. Table 4 of
Nieto-Miguel, Mol Vis 2011; 17:2102-2117.
Table 4. Molecules significantly associated with relevant functions and diseases.
| Category | B-H P-value | Molecules |
|---|---|---|
| Cellular Development | 3.49E-13–1.53E-02 | 37 |
| Tissue Development | 3.61E-10–1.53E-02 | 31 |
| Organismal Development | 3.91E-09–4.75E-03 | 22 |
| Embryonic Development | 2.37E-08–1.53E-02 | 26 |
| Cell Death | 3.61E-08–1.53E-02 | 35 |
| Gene Expression | 2.67E-07–1.53E-02 | 32 |
| Cellular Assembly and Organization | 2.67E-07–1.53E-02 | 22 |
| Nervous System Development and Function | 2.67E-07–1.53E-02 | 29 |
| Cancer | 3.1E-07–1.53E-02 | 40 |
| Cellular Growth and Proliferation | 5.45E-07–1.53E-02 | 39 |
| Cell Morphology | 5.45E-07–1.53E-02 | 23 |
| Cell Cycle | 1.15E-06–1.53E-02 | 17 |
| Organ Development | 1.69E-06–1.36E-02 | 20 |
| Skeletal and Muscular Disorders | 3.01E-06–1.53E-02 | 11 |
| Renal and Urological Disease | 4.17E-06–1.36E-02 | 7 |
| Genetic Disorder | 5.66E-06–1.53E-02 | 39 |
| Developmental Disorder | 7.55E-06–1.53E-02 | 17 |
| Connective Tissue Development and Function | 4.09E-05–1.53E-02 | 21 |
| Skeletal and Muscular System Development and Function | 4.09E-05–1.5E-02 | 17 |
| Hematological System Development and Function | 8.41E-05–1.53E-02 | 18 |
| Hematopoiesis | 8.41E-05–1.53E-02 | 13 |
| Neurologic Disease | 1.35E-04–1.53E-02 | 27 |
| Lymphoid Tissue Structure and Development | 1.86E-04–1.53E-02 | 9 |
| Auditory and Vestibular System Development and Function | 2.51E-04–8.77E-03 | 5 |
| Cell-To-Cell Signaling and Interaction | 2.92E-04–1.53E-02 | 23 |
| Cellular Movement | 2.98E-04–1.53E-02 | 22 |
| Cellular Function and Maintenance | 3.24E-04–1.53E-02 | 14 |
| Cardiovascular System Development and Function | 3.82E-04–1.53E-02 | 14 |
| Hepatic System Disease | 3.82E-04–1.53E-02 | 14 |
| Reproductive System Disease | 5.45E-04–1.53E-02 | 19 |
| Gastrointestinal Disease | 5.48E-04–1.53E-02 | 21 |
| Tissue Morphology | 6.35E-04–1.53E-02 | 18 |
| Energy Production | 6.56E-04–6.56E-04 | 3 |
| Molecular Transport | 6.56E-04–1.53E-02 | 3 |
| Nucleic Acid Metabolism | 6.56E-04–1.53E-02 | 4 |
| Small Molecule Biochemistry | 6.56E-04–1.53E-02 | 9 |
| Organ Morphology | 1.04E-03–1.53E-02 | 13 |
| Tumor Morphology | 1.13E-03–1.53E-02 | 10 |
| Metabolic Disease | 1.33E-03–1.33E-03 | 3 |
| DNA Replication. Recombination. and Repair | 1.5E-03–1.53E-02 | 11 |
| Connective Tissue Disorders | 1.54E-03–7.79E-03 | 10 |
| Humoral Immune Response | 2.21E-03–3.6E-03 | 4 |
| Visual System Development and Function | 2.21E-03–7.79E-03 | 4 |
| Psychological Disorders | 2.25E-03–2.25E-03 | 6 |
| Infection Mechanism | 2.47E-03–9.23E-03 | 4 |
| Post-Translational Modification | 2.69E-03–1.53E-02 | 11 |
| Carbohydrate Metabolism | 2.81E-03–2.81E-03 | 5 |
| Lipid Metabolism | 2.81E-03–2.81E-03 | 3 |
| Drug Metabolism | 2.81E-03–1.53E-02 | 3 |
| Endocrine System Development and Function | 2.81E-03–1.53E-02 | 4 |
| Hair and Skin Development and Function | 3.04E-03–1.53E-02 | 6 |
| Reproductive System Development and Function | 3.45E-03–1.53E-02 | 4 |
| Hematological Disease | 5.19E-03–1.53E-02 | 8 |
| Cardiovascular Disease | 5.28E-03–5.28E-03 | 4 |
| Cell-mediated Immune Response | 6.31E-03–1.3E-02 | 5 |
| Organismal Injury and Abnormalities | 6.88E-03–6.88E-03 | 3 |
| Digestive System Development and Function | 7.14E-03–7.14E-03 | 3 |
| Organismal Survival | 7.53E-03–7.53E-03 | 12 |
| Hepatic System Development and Function | 8.76E-03–8.76E-03 | 2 |
| Respiratory System Development and Function | 8.76E-03–1.53E-02 | 3 |
| Antigen Presentation | 1.23E-02–1.23E-02 | 2 |
| Inflammatory Disease | 1.53E-02–1.53E-02 | 2 |
| Cell Signaling | 1.53E-02–1.53E-02 | 2 |
| Protein Trafficking | 1.53E-02–1.53E-02 | 2 |
| Vitamin and Mineral Metabolism | 1.53E-02–1.53E-02 | 2 |
| Renal and Urological System Development and Function | 1.53E-02–1.53E-02 | 2 |
| Auditory Disease | 1.53E-02–1.53E-02 | 1 |
| Cellular Compromise | 1.53E-02–1.53E-02 | 1 |
| Dermatological Diseases and Conditions | 1.53E-02–1.53E-02 | 1 |
| Immune Cell Trafficking | 1.53E-02–1.53E-02 | 1 |
| RNA Post-Transcriptional Modification | 1.53E-02–1.53E-02 | 1 |